中图分类号R979.1 文献标志码A 文章编号 1001-0408(2025)09-1135-06

    DOI10.6039/j.issn.1001-0408.2025.09.20

    ABSTRACTOBJECTIVETo analyze theeficacyand safetyof luspatercept in the treatment of myelodysplastic syndromes (MDS)anemia，andprovidereferenceforclinicalmedication.METHODSTheliteraturerelatedtoluspaterceptforMDSanemiain PubMed，CochraneLibrary，EmbaseandWebof Science weresearchedbycomputer，and thesearch timewas from the establishmentofthedatabasetoJanuary 2024.Thequalityof literaturewasevaluatedaftertheywerescrenedaccordingto inclusionand exclusioncriteria，thesingle-grouprate meta-analysisandsensitivityanalysis were performedbyusing RevMan5.4 software，andthesubgroupanalysis wasconducted.RESULTSAtotalof756patientsin9articleswereincludedinthisstudyTe results of meta-analysis showed that the proportion of MDS patients who reached ? 8 weeks of red blood cell transfusion independence(RBC-TI)was 4 6 % after using luspatercept [ 9 5 % C ] (0.28，0.64)， Plt;0 . 0 0 0 01]. The proportion of MDS patients whose hematological improvement in erythrocyte(HI-E)was 5 9 % 二 [ 9 5 % C ] (0.43，0.74)， Plt;0 . 0 0 0 01].Among them ......